Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.

Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts. PLoS One (2014) 0.86

PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor. J Nucl Med (2015) 0.85

High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts. PLoS One (2015) 0.85

c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World J Gastroenterol (2014) 0.83

Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma. PLoS One (2014) 0.78

Development of Tivantinib as Treatment for Hepatocellular Carcinoma. J Clin Transl Hepatol (2013) 0.77

Proteinase-activated receptor 1- and 4-promoted migration of Hep3B hepatocellular carcinoma cells depends on ROS formation and RTK transactivation. J Cancer Res Clin Oncol (2014) 0.76

Clinical implications of basic research in hepatocellular carcinoma. J Hepatol (2015) 0.76

Hepatocyte growth factor and alternative splice variants - expression, regulation and implications in osteogenesis and bone health and repair. Expert Opin Ther Targets (2016) 0.75

Novel implications in the treatment of hepatocellular carcinoma. Ann Gastroenterol (2016) 0.75

The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy. Oncotarget (2015) 0.75

Mechanism of QHF-cisplatin against hepatocellular carcinoma in a mouse model. World J Gastroenterol (2015) 0.75

Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. Front Immunol (2017) 0.75

Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date. J Hepatocell Carcinoma (2016) 0.75

Korean Red Ginseng extract induces angiogenesis through activation of glucocorticoid receptor. J Ginseng Res (2016) 0.75

Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives. J Clin Transl Hepatol (2017) 0.75

Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma. Diseases (2015) 0.75

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16

Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (1991) 8.68

Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature (1987) 6.26

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23

Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A (2008) 5.08

Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell (1991) 4.98

Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature (1995) 4.68

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell (2012) 4.47

Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17

The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene (2010) 4.00

Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther (2011) 3.53

Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2012) 3.39

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31

Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A (2004) 2.77

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol (2011) 2.69

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell (2004) 2.61

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov (2012) 2.57

C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer (2005) 2.25

HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem (2003) 2.08

c-Met is essential for wound healing in the skin. J Cell Biol (2007) 1.98

The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell (2004) 1.93

Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest (2000) 1.90

Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A (2003) 1.90

Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol (2011) 1.87

Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res (2008) 1.82

Cancer therapy: can the challenge be MET? Trends Mol Med (2005) 1.81

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants. Oncogene (2004) 1.78

Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol (2012) 1.77

Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res (1999) 1.74

Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer (2005) 1.73

From Tpr-Met to Met, tumorigenesis and tubes. Oncogene (2007) 1.69

Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade--results of an explorative CGH meta-analysis. Br J Cancer (2005) 1.64

Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol (2001) 1.64

Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology (2009) 1.56

Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology (1997) 1.50

Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 1.45

Identification of a competitive HGF antagonist encoded by an alternative transcript. Science (1991) 1.44

Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A (2003) 1.42

Abrogation of Fas-induced fulminant hepatic failure in mice by hepatocyte growth factor. Biochem Biophys Res Commun (1998) 1.37

c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem (2007) 1.34

Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. Oncogene (1997) 1.34

Grb2 signaling in cell motility and cancer. Expert Opin Ther Targets (2008) 1.32

An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest (2004) 1.25

Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem (1993) 1.21

Scatter factors and invasive growth. Semin Cancer Biol (2001) 1.21

Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology (1994) 1.21

Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog (2003) 1.19

MET signaling pathway: a rational target for cancer therapy. J Clin Oncol (2011) 1.17

Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation: a retrospective study. J Gastrointest Surg (2007) 1.16

Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res (1997) 1.16

Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. Cancer Res (2002) 1.14

Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos (2008) 1.12

u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer (2000) 1.12

Inactivation of p16INK4 in hepatocellular carcinoma. Hepatology (1996) 1.11

c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology (1994) 1.11

Cooperative interaction between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses. J Biol Chem (1998) 1.11

Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res (2010) 1.05

A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist. Proc Natl Acad Sci U S A (2007) 1.03

Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem (2001) 1.03

P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol (2002) 1.02

Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res (2007) 1.01

Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma. Hepatogastroenterology (2008) 1.00

NK4 gene therapy targeting HGF-Met and angiogenesis. Front Biosci (2008) 0.99

Structural basis for agonism and antagonism of hepatocyte growth factor. Proc Natl Acad Sci U S A (2010) 0.99

Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in C-viral chronic liver diseases. Cancer (2002) 0.98

Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. Mol Cell Biol (2000) 0.98

MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis. J Hepatol (1993) 0.96

Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. Biochem J (1997) 0.96

The HGF receptor/Met tyrosine kinase is a key regulator of dendritic cell migration in skin immunity. J Immunol (2012) 0.94

A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. Int J Cancer (2011) 0.93

Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver (1999) 0.93

Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci (2009) 0.93

Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Int J Cancer (2010) 0.93

Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis. Eur Cytokine Netw (2010) 0.91

Directed discovery of agents targeting the Met tyrosine kinase domain by virtual screening. J Med Chem (2009) 0.89

Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET. J Biol Chem (2011) 0.88

Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinoma. J Gastroenterol (2004) 0.88

Adrenergic stimulation of hepatocyte growth factor expression. Biochem Biophys Res Commun (1999) 0.87

Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma. Pharmacol Res (2011) 0.84

EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells. Transl Oncol (2012) 0.83

Growth factor pathways in development and progression of hepatocellular carcinoma. Front Biosci (Schol Ed) (2012) 0.82

In vivo imaging of mesenchymal-epithelial transition factor (c-Met) expression using an optical imaging system. Bioconjug Chem (2009) 0.82

In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptor. J Med Chem (2010) 0.80

[Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma]. Zhonghua Wai Ke Za Zhi (2006) 0.77

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol (2011) 2.59

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs (2014) 0.85

Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer. Cancer Med (2014) 0.81